 Arovella Therapeutics Ltd ASX:ALA has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide targeting technology and its CAR19-iNKT cell therapy technologies. With more than 15 years of experience in the field of immunology under her belt, Dr Bharathan has spent the last 12 years working in the development of cell therapies with various organisations, such as the US Department of Health, Celgene and Cellectis NASDAQ:CLLS Cellectis NASDAQ:CLLS. 